- Statement in connection with Botulinum Toxin and Cosmetic Fillers (Children) Private Member’s Bill 2019-21
Statement in connection with Botulinum Toxin and Cosmetic Fillers (Children) Private Member’s Bill 2019-21
The British College of Aesthetic Medicine (BCAM) is the leading College representing clinicians working in the Aesthetic Medicine specialty. BCAM’s mission is to help make Aesthetic Medicine
safer, more ethical and more accessible to the general public.
The College welcomes the Botulinum Toxin and Cosmetic Fillers (Children) Bill as a welcome step toward long-overdue tightening of regulation surrounding the accessibility of aesthetic interventions, particularly from non-medically qualified practitioners.
The Bill would create an offence for the administration of botulinum toxins or cosmetic fillers to people under 18 years of age unless there is an assessed medical need from a statutorily regulated
healthcare professional. BCAM lends its weight to the existing backing of the Department of Health & Social Care (DHSC).
BCAM President Dr Uliana Gout says: “BCAM fully endorses the Private Member’s Bill and increased regulation in our specialty. BCAM has a good professional relationship with DHSC and just this week have agreed to extend our national audit data collection of Aesthetic Medicine to cover under 18 year-old patient treatments. This will support the information gathering efforts to generate national statistics in this critical area.”
Recent data from BCAM’s annual audit reveals 43% of members polled have seen new patients presenting to them with complications following treatments by beauty therapists, the most popular
patient treatment choices being Botulinum Toxin (Botox)® and Dermal Fillers.
Mr Greg White, Chief Executive of the British College of Aesthetic Medicine, says: “Let us be quite clear - patient safety is paramount. Dermal fillers in particular are plain dangerous in the wrong hands. Protecting vulnerable patients is not optional. Our survey yet again underlines the vital issue of agreeing a wider regulatory regime which supports controlled access to prescription medicines and which differentiates aesthetic medicine from beauty therapists, spas and salons which we continue to monitor and call out. The Bill is an important step forward which we fully support.”
View other News